Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Toujeo does carry a somewhat lower hypoglycemia risk compared to Lantus, thanks to its more gradual absorption profile
It raises broader questions about how innovation is distributed, and who benefits first when new therapies emerge
Novo Nordisks technology for making insulin long-acting had failed when applied to GLP-1 and Knudsen had to start over
The cardiovascular and renal protective benefits observed with certain GLP-1 medications also diminish after discontinuation
US$ 28.75
US$ 27.69
US$ 20.87
US$ 28.23
